# Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

> **NCT03099161** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 10 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** preladenant
- **BIOLOGICAL:** pembrolizumab

## Key facts

- **NCT ID:** NCT03099161
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-27
- **Primary completion:** 2017-11-24
- **Final completion:** 2018-02-21
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The data did not support study endpoints
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099161, "Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03099161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*